Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · Small Molecule · Small Molecule

What is Scherersol delivery systems?

Scherersol delivery systems is a small molecule developed by Cardinal Health, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesPolysol, Quadrisol, Cosol
CompanyCardinal Health, Inc.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved

Therapeutic Indications

Scherersol delivery systems is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedJournal of medical Internet research2026-10-22

Discover to Deliver Pediatric Futures: Viewpoints of Future Medicine From a Pediatric Health Care System.

Sincock Watkins Vanessa V, Chang Ken K, Sarff Laura L, Vavroch Jared J et al.

Pediatric health care systems face increasing uncertainty driven by rapid technological change, workforce shifts and shortages, environmental threats, and evolving family and community needs. Pediatrics requires future-focused considerations that go beyond adult systems, including family-centered care, developmental trajectories, and long-term societal impacts on child well-being. While the future cannot be predicted, futures medicine methods offer structured approaches to anticipate change and support proactive, values-driven planning. This Viewpoint describes the application of pediatric futures methods within an academic, independent nonprofit pediatric health system and proposes a practical framework that connects future readiness to strategic decision-making and daily care delivery. Futures medicine methods are not new in pediatric health care but may not be visible from the front line of care delivery, which provides an opportunity for clinical, operational, administrative, and enterprise leaders to implement these methods in their workflows. This paper introduces the discover to deliver pediatric futures framework, a continuum that links long-range futures discovery to near-term strategic planning, operational design, implementation, and outcome demonstration, emphasizing future methods and activities for applicable use.

PubMedBioconjugate chemistry2026-10-22

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

Smith Brooke E BE, Lou Jinchao J, Phillips Miranda A MA, Sagar Ruhani R et al.

Many clinically used chemotherapeutics, including doxorubicin, suffer from dose-limiting toxicities, poor biodistribution, and limited control over intracellular activation. To mitigate these challenges, two primary delivery strategies have been widely explored: prodrug design and liposomal encapsulation. Prodrugs can improve solubility, pharmacokinetics, and site-selective activation, while liposomes enhance circulation time and reduce off-target exposure. However, each approach presents limitations when employed independently. Prodrugs may introduce stability or solubility concerns and can undergo premature activation, whereas liposomal formulations often rely on passive release mechanisms and may exhibit incomplete or non-specific cargo leakage. In the current work, we sought to develop a synergistic delivery approach that integrates a chemically responsive prodrug directly within the liposomal membrane that responds to reactive oxygen species (ROS) highly upregulated within diseased cells. We report a ROS-responsive doxorubicin lipid prodrug conjugate, ROSDoxL, which is incorporated within the liposomal bilayer, enabling membrane-embedded therapeutic loading rather than aqueous core encapsulation. The prodrug design features a boronate caging group that undergoes oxidation in the presence of elevated reactive oxygen species, triggering a self-immolative release of doxorubicin. A non-responsive control doxorubicin lipid, DoxL, lacking the boronate moiety, was used to evaluate the specific ROS-mediated uncaging mechanism. ESI-HRMS studies confirmed ROS-dependent cleavage of ROSDoxL, while liposomal characterization and cellular studies demonstrated functional delivery and concentration-dependent cytotoxicity in A375 melanoma cells comparable to free doxorubicin. Our membrane-integrated liposomal prodrug approach provides a modular strategy for coupling disease-associated biochemical signals to controlled drug activation, advancing liposomal systems beyond passive carriers towards stimulus-responsive therapeutic delivery.

PubMedMalawi medical journal : the journal of Medical Association of Malawi2026-10-22

Key Factors Influencing Intention to Use Digital Health Systems Among Healthcare Workers in Malawi.

Nkoloma Mayamiko M, Gombachika Harry H, Mikeka Chomora C, Maluwa Alfred A

Digital Health systems (DHS) have the potential to strengthen healthcare delivery, yet their adoption remains limited in many low- and middle-income countries. Despite progress in digital health implementation, Malawi continues to face challenges related to effective use of DHS. This study investigates the key factors influencing healthcare workers' intention to use DHS in Malawi. This was a cross-sectional quantitative design that used a structured questionnaire to collect data from a sample of 615 healthcare workers across Malawi. Factor analysis and reliability testing were conducted to assess construct validity and internal consistency. Multiple linear regression was used to identify factors influencing intention to use DHS, while generalized structural equation modelling (GSEM) examined relationships involving categorical variables. The results indicated that healthcare workers' intention to use DHS is influenced by several factors including, perceived ease of use (β = 0.358, p <0.001), perceived usefulness (β = 0.284, p = 0.001), job relevance (β = 0.274, p = 0.001) and subjective norms (β = 0.127, p <0.001). These findings suggest that healthcare workers are more likely to use DHS when they perceive them as useful, relevant to their daily work, easy to use, and are supported by their peers. In contrast, computer anxiety indicated a significant negative effect (β = -0.061, p = 0.001), suggesting that higher levels of computer anxiety reduce the likelihood of DHS use. Demographic and contextual factors, including gender, age, and education level were not significant factors influencing DHS. These findings highlight the importance of aligning digital health systems with healthcare workers' job roles, ensuring system usability, and leveraging social influence to promote adoption. Addressing computer anxiety through targeted training and capacity building may also enhance digital confidence and sustained system use.

PubMedMalawi medical journal : the journal of Medical Association of Malawi2026-10-22

Conflict of Interest vs Conflict of Incentives: Rethinking Dual Practice in Light of Malawi's Presidential Executive Order No. 1 of 2026.

Patel Parth K PK, Nair Supriya S

Dual practice-where health professionals simultaneously participate in public and private healthcare markets-is common in many health systems but presents complex governance challenges. In 2026, the Government of Malawi issued Presidential Executive Order No. 1 of 2026, prohibiting public health workers from soliciting informal payments in public facilities and restricting their ownership or financial interests in private healthcare establishments. The policy has generated significant national debate regarding its implications for health system governance and workforce incentives. This commentary examines the policy rationale and potential implications of the Executive Order, focusing on the tension between addressing conflicts of interest and maintaining appropriate incentives for health workforce retention. Drawing on international literature and comparative policy experiences, the commentary situates Malawi's reform within the broader global discourse on dual practice regulation. Evidence from multiple health systems indicates that physician ownership of private facilities can introduce structural conflicts of interest that undermine public sector performance through patient diversion, reduced public sector effort, and erosion of public trust. However, outright restrictions on private sector engagement may also carry unintended consequences in settings where public sector remuneration is limited and specialist workforce shortages are acute. International experiences demonstrate that successful regulation of dual practice requires careful alignment of governance mechanisms, workforce incentives, and health system accountability. Malawi's Executive Order represents a decisive attempt to strengthen the integrity of public healthcare delivery by addressing ownership-based conflicts of interest. Its long-term effectiveness will depend on balanced implementation, transparent regulatory guidance, and complementary reforms that address workforce incentives and health system capacity. The current debate offers an opportunity to move beyond polarized narratives and instead focus on building a governance framework that simultaneously protects public trust and supports a sustainable health workforce.

PubMedBioconjugate chemistry2026-10-22

Development of a Hyaluronic Acid-Retinol Conjugate for Enhanced Photostability and Transdermal Delivery.

Park Chaeheon C, Lee Seungchan S, Jung Seung Oh SO, Lee Yujin Y et al.

Despite its potent anti-aging efficacy, the practical application of retinol (ROH) remains highly restricted by its poor photostability, low aqueous solubility, and concentration-dependent cytotoxicity. Herein, we report the synthesis of a hyaluronic acid-retinol (HA-ROH) conjugate to overcome these limitations and improve transdermal delivery. The successful conjugation was confirmed via proton nuclear magnetic resonance (1H NMR) spectroscopy, high-performance liquid chromatography (HPLC) and Fourier-transform infrared spectroscopy (FT-IR). Notably, the HA-ROH conjugate exhibited remarkable photostability under UVA irradiation compared to free retinol. HA-ROH presented a sustained, hyaluronidase-responsive ROH release profile, indicating its potential as an enzyme-responsive controlled delivery system. Furthermore, the conjugation significantly mitigated the cytotoxicity of retinol in both HaCaT keratinocytes and human dermal fibroblasts. The conjugate suppressed matrix metalloproteinase-1 (MMP-1) expression more effectively than free ROH. In vitro cellular uptake and ex vivo skin permeation studies demonstrated enhanced transdermal delivery of the HA-ROH conjugate. Taken together, these results suggest that the HA-ROH conjugate is a highly promising, stable, and safe candidate for advanced dermatologic and cosmetic applications.

PubMedChemistry & biodiversity2026-10-22

A Comprehensive Review on Ferula oopoda (Boiss. and Buhse) Boiss.: Bioactive Compounds and Pharmacological Significance.

Ali Muhammad M, Permanasari Setya Widi Ayuning SWA, Niaz Shah Iram SI, Baiseitova Aizhamal A et al.

Ferula oopoda (Boiss. and Buhse) Boiss. is an ethnomedicinally important species widely used in Central and South Asia for the treatment of gastrointestinal, respiratory, neurological, and parasitic disorders. Despite its extensive traditional applications, comprehensive scientific evaluation of its pharmacological potential remains limited. This review systematically analyzes, for the first time, the available literature on the botany, phytochemical composition, ethnomedicinal uses, and pharmacological activities of F. oopoda, while highlighting current research gaps and future perspectives for drug discovery. To date, thirty-three secondary metabolites have been isolated from F. oopoda, including sesquiterpene lactones (STLs), sesquiterpenoids, monoterpene-phenyl esters, and phenolic acid glucosides. In addition, gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) analyses detected several low-molecular-weight constituents in essential oils and organic extracts. Both crude extracts and isolated compounds have displayed a broad spectrum of biological activities, including antibacterial, anti-plasmodial, antioxidant, anti-inflammatory, antimutagenic, and antiulcer effects. However, detailed mechanistic studies, pharmacokinetic investigations, and in vivo validations remain limited. Future research integrating structure-activity relationship studies and molecular target identification with omics-based approaches (e.g., metabolomics), in silico techniques such as molecular docking, and nano-drug delivery systems will be essential to advance its development into evidence-based therapeutic agents.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Scherersol delivery systems